Published in Blood on November 05, 2007
Janus kinases in immune cell signaling. Immunol Rev (2009) 3.60
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov (2011) 2.38
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
Therapeutic targeting of Janus kinases. Immunol Rev (2008) 2.03
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest (2010) 1.93
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood (2009) 1.82
Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program (2009) 1.74
Stat5 signaling specifies basal versus stress erythropoietic responses through distinct binary and graded dynamic modalities. PLoS Biol (2012) 1.59
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood (2010) 1.42
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res (2009) 1.39
Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia (2011) 1.22
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med (2010) 1.19
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med (2008) 1.10
FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol (2011) 1.09
Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One (2010) 1.06
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist (2011) 1.05
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther (2011) 1.05
AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood (2010) 1.05
Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS One (2011) 1.03
Human papillomavirus E7 oncoprotein increases production of the anti-inflammatory interleukin-18 binding protein in keratinocytes. J Virol (2014) 1.00
Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis. J Immunol (2009) 1.00
Genetics of myeloproliferative neoplasms. Cancer J (2014) 0.98
JAK2 inhibitors: what's the true therapeutic potential? Blood Rev (2010) 0.97
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer (2011) 0.97
Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res (2011) 0.97
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res (2010) 0.95
Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection. Blood (2012) 0.93
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia (2008) 0.93
Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol (2013) 0.91
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT (2013) 0.91
Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC. Cancer Biol Ther (2010) 0.87
Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy. Innov Clin Neurosci (2014) 0.86
Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opin Ther Targets (2012) 0.86
Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies. Curr Oncol Rep (2009) 0.86
A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden. PLoS One (2012) 0.86
PRK1/PKN1 controls migration and metastasis of androgen-independent prostate cancer cells. Oncotarget (2014) 0.85
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer (2010) 0.85
Current and future treatment options for polycythemia vera. Ann Hematol (2015) 0.84
Repositioning: the fast track to new anti-malarial medicines? Malar J (2014) 0.83
Efficacy of vorinostat in a murine model of polycythemia vera. Blood (2012) 0.83
Myelofibrosis 2012: it's complicated. Ther Adv Hematol (2012) 0.83
Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production. J Biol Chem (2011) 0.83
Blockade of glioma proliferation through allosteric inhibition of JAK2. Sci Signal (2013) 0.83
Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells. PLoS One (2012) 0.82
A potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs (2011) 0.81
Establishing the role of tyrosine kinase 2 in cancer. Oncoimmunology (2013) 0.81
ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway. Mol Biol Cell (2010) 0.81
Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomed Nanotechnol (2013) 0.80
Profile of pacritinib and its potential in the treatment of hematologic disorders. J Blood Med (2014) 0.80
Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation. Haematologica (2013) 0.79
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells. Breast Cancer Res (2014) 0.78
JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms. Adv Hematol (2012) 0.78
Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia. Thromb J (2009) 0.78
The c-Myb target gene neuromedin U functions as a novel cofactor during the early stages of erythropoiesis. Blood (2011) 0.78
Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo. Cancer Biol Ther (2015) 0.78
A randomised assessment of adding the kinase inhibitor lestaurtinib to 1st-line chemotherapy for FLT3-mutated AML. Blood (2016) 0.77
JAK2 inhibitors: are they the solution? Clin Lymphoma Myeloma Leuk (2011) 0.77
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Ther Adv Hematol (2012) 0.77
JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg? Am J Hematol (2012) 0.77
Advances in paediatric cancer treatment. Transl Pediatr (2014) 0.76
A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease. Leukemia (2015) 0.76
Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes. PLoS One (2014) 0.76
JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target? Ther Adv Hematol (2011) 0.76
Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget (2016) 0.75
Can we control JAK? Blood (2008) 0.75
Upregulation of Nicotinic Acetylcholine Receptor alph4+beta2 through a Ligand-Independent PI3Kbeta Mechanism That Is Enhanced by TNFalpha and the Jak2/p38Mapk Pathways. PLoS One (2015) 0.75
Novel and emerging therapies for the treatment of polycythemia vera. Expert Rev Hematol (2014) 0.75
Natural Products Diversity of Marine Ascidians (Tunicates; Ascidiacea) and Successful Drugs in Clinical Development. Nat Prod Bioprospect (2017) 0.75
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Some speculations on the myeloproliferative syndromes. Blood (1951) 7.78
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell (2002) 5.44
Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst (1960) 4.15
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 3.76
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood (2006) 3.37
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med (2002) 3.08
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 2.76
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia (2006) 1.90
Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med (1998) 1.85
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood (2001) 1.73
Flow cytometric analysis of human bone marrow: I. Normal erythroid development. Blood (1987) 1.60
Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood (2001) 1.45
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood (2005) 1.44
Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet (2002) 1.40
Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood (2006) 1.40
Stat3 cleavage by caspases: impact on full-length Stat3 expression, fragment formation, and transcriptional activity. J Biol Chem (2006) 1.05
Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL. Blood (1996) 1.04
Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. Br J Haematol (2001) 1.01
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med (2005) 4.10
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med (2012) 3.15
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96
Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood (2003) 2.93
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol (2007) 2.90
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 2.76
Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood (2007) 2.65
Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol (2006) 2.55
Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol (2004) 2.54
Variation in the detection of serrated polyps in an average risk colorectal cancer screening cohort. Am J Gastroenterol (2010) 2.44
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell (2009) 2.39
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood (2008) 2.26
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med (2004) 2.23
The clinical significance of serrated polyps. Am J Gastroenterol (2010) 2.21
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood (2007) 2.14
Sertoli cells from non-obstructive azoospermia and obstructive azoospermia patients show distinct morphology, Raman spectrum and biochemical phenotype. Hum Reprod (2013) 2.06
Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J Clin Invest (2002) 1.98
Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene (2002) 1.93
mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood (2008) 1.88
Hematopoietic stem-cell contribution to ectopic skeletogenesis. J Bone Joint Surg Am (2007) 1.83
Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell (2006) 1.76
A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma (2006) 1.67
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood (2014) 1.64
mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood (2005) 1.63
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther (2003) 1.59
Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res (2007) 1.56
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood (2007) 1.54
Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood (2004) 1.53
Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. J Clin Invest (2009) 1.52
APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol (2002) 1.52
Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. Blood (2011) 1.49
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res (2008) 1.48
Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood (2007) 1.48
Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res (2004) 1.44
NF-Ya activates multiple hematopoietic stem cell (HSC) regulatory genes and promotes HSC self-renewal. Proc Natl Acad Sci U S A (2005) 1.44
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res (2009) 1.42
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood (2013) 1.41
Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 hours. Cancer Biol Ther (2010) 1.40
Bone and blood vessels: the hard and the soft of hematopoietic stem cell niches. Cell Stem Cell (2009) 1.39
Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. Blood (2009) 1.37
Bone morphogenetic protein signaling regulates the size of hair follicles and modulates the expression of cell cycle-associated genes. Proc Natl Acad Sci U S A (2006) 1.35
Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype. Am J Surg Pathol (2004) 1.30
Stem cell transplantation (cord blood transplants). Hematology Am Soc Hematol Educ Program (2004) 1.28
c-Myb contributes to G2/M cell cycle transition in human hematopoietic cells by direct regulation of cyclin B1 expression. Mol Cell Biol (2007) 1.26
A common genetic mechanism in malignant bone marrow diseases. N Engl J Med (2009) 1.23
NF-Y cooperates with USF1/2 to induce the hematopoietic expression of HOXB4. Blood (2003) 1.23
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem (2008) 1.22
BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell (2004) 1.22
Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood (2010) 1.21
Hyperplastic polyps, serrated adenomas, and the serrated polyp neoplasia pathway. Am J Gastroenterol (2004) 1.20
Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. Biol Blood Marrow Transplant (2007) 1.18
Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J Immunol (2005) 1.17
Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Res (2007) 1.16
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res (2011) 1.14
The many faces of Janus kinase. Biochem Pharmacol (2011) 1.13
Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A (2014) 1.12
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther (2007) 1.11
Multiplex RT-PCR for the detection of leukemia-associated translocations: validation and application to routine molecular diagnostic practice. J Mol Diagn (2003) 1.10
A new bone to pick: osteoblasts and the haematopoietic stem-cell niche. Bioessays (2004) 1.06
Molecular pathways regulating the self-renewal of hematopoietic stem cells. Exp Hematol (2004) 1.06
Medical hyperspectral imaging to facilitate residual tumor identification during surgery. Cancer Biol Ther (2007) 1.05
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther (2011) 1.05
Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol (2012) 1.02
Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res (2007) 1.02
Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood (2004) 1.02
Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J Immunol (2011) 1.02
Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. Blood (2004) 1.01
NF-Y is necessary for hematopoietic stem cell proliferation and survival. Blood (2011) 1.01
CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease. J Immunol (2007) 1.00
BCR-ABL kinase is dead; long live the CML stem cell. J Clin Invest (2010) 1.00
The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. Clin Cancer Res (2002) 0.99
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res (2003) 0.98
Dynamic evolution of clonal epialleles revealed by methclone. Genome Biol (2014) 0.97
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res (2003) 0.96
Blood cells from Friedreich ataxia patients harbor frataxin deficiency without a loss of mitochondrial function. Mitochondrion (2010) 0.96
Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia. Cancer Cell (2011) 0.94
Interferon regulatory factor-8-driven myeloid differentiation is regulated by 12/15-lipoxygenase-mediated redox signaling. Exp Hematol (2010) 0.93
Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem Biophys Res Commun (2004) 0.93
TAT-mediated transduction of NF-Ya peptide induces the ex vivo proliferation and engraftment potential of human hematopoietic progenitor cells. Blood (2010) 0.93
TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle. Blood (2002) 0.93
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood (2007) 0.93
A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody. J Immunol (2008) 0.93
The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin Cancer Res (2002) 0.92
Generation of male germ cells from induced pluripotent stem cells (iPS cells): an in vitro and in vivo study. Asian J Androl (2012) 0.92
Association of XRCC3 Thr241Met polymorphisms and gliomas risk: evidence from a meta-analysis. Asian Pac J Cancer Prev (2013) 0.91
Coffee consumption and prostate cancer risk: an updated meta-analysis. Cancer Causes Control (2014) 0.91